A Placebo-Controlled, Blinded and Randomised Study on the Effects of Recombinant Human Thyrotropin on Quality of Life in the Treatment of Thyroid Cancer | Zendy

Birte Nygaard | Zendy; Lars Bastholt | Zendy; Finn Noe Bennedbæk | Zendy; Tobias Wirenfeldt Klausen | Zendy; Jens Bentzen | Zendy

Open Access

A Placebo-Controlled, Blinded and Randomised Study on the Effects of Recombinant Human Thyrotropin on Quality of Life in the Treatment of Thyroid Cancer

Author(s) -

Birte Nygaard,

Lars Bastholt,

Finn Noe Bennedbæk,

Tobias Wirenfeldt Klausen,

Jens Bentzen

Publication year - 2013

Publication title -

european thyroid journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.23

H-Index - 10

eISSN - 2235-0802

pISSN - 2235-0640

DOI - 10.1159/000354803

Subject(s) - medicine , placebo , thyroid cancer , recombinant dna , quality of life (healthcare) , oncology , clinical trial , cancer , endocrinology , pathology , alternative medicine , nursing , biochemistry , chemistry , gene

It is well known that thyroid hormone withdrawal (THW) in thyroid cancer patients can induce a decrease in quality of life (QOL). Recombinant human thyrotropin (rh-TSH) has been used to avoid this; however, no blinded studies have ever documented the effect.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research